These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23134386)

  • 61. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.
    Janjigian YY; Braghiroli MI
    Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HER2 expression and efficacy of T-DM1.
    Montemurro F
    Breast Cancer Res; 2014 Dec; 16(6):478. PubMed ID: 25472666
    [No Abstract]   [Full Text] [Related]  

  • 63. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Trastuzumab emtansine in HER2-positive metastatic breast cancer.
    Montemurro F
    Lancet Oncol; 2017 Jun; 18(6):696-697. PubMed ID: 28526537
    [No Abstract]   [Full Text] [Related]  

  • 65. Medicine: Eyes on the target.
    Eisenstein M
    Nature; 2015 Nov; 527(7578):S110-2. PubMed ID: 26580159
    [No Abstract]   [Full Text] [Related]  

  • 66. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci F; Le Tourneau C
    Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892
    [No Abstract]   [Full Text] [Related]  

  • 67. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
    Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
    Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
    Piwko C; Prady C; Yunger S; Pollex E; Moser A
    Clin Drug Investig; 2015 Aug; 35(8):487-93. PubMed ID: 26123628
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Enthusiasm for antibody-drug conjugates.
    Tuma RS
    J Natl Cancer Inst; 2011 Oct; 103(20):1493-4. PubMed ID: 21972230
    [No Abstract]   [Full Text] [Related]  

  • 70. Treatment combinations for HER2-positive breast cancer.
    Pegram M
    Oncology (Williston Park); 2013 Apr; 27(4):258, 260. PubMed ID: 23781688
    [No Abstract]   [Full Text] [Related]  

  • 71. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
    Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
    Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Third-generation antibody drug conjugates for cancer therapy--a balancing act.
    Vankemmelbeke M; Durrant L
    Ther Deliv; 2016; 7(3):141-4. PubMed ID: 26893243
    [No Abstract]   [Full Text] [Related]  

  • 73. Emerging Therapeutic Strategies in Breast Cancer.
    Cox K; Alford B; Soliman H
    South Med J; 2017 Oct; 110(10):632-637. PubMed ID: 28973703
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
    Force J; Saxena R; Schneider BP; Storniolo AM; Sledge GW; Chalasani N; Vuppalanchi R
    J Clin Oncol; 2016 Jan; 34(3):e9-12. PubMed ID: 24778392
    [No Abstract]   [Full Text] [Related]  

  • 75. Trastuzumab in breast cancer.
    Banna GL; Santoro A
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
    [No Abstract]   [Full Text] [Related]  

  • 76. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
    Lambert JM; Chari RV
    J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reply to a. Avan et Al.
    Baselga J; Clark E; Kiermaier A; Swain SM
    J Clin Oncol; 2015 May; 33(15):1712. PubMed ID: 25870094
    [No Abstract]   [Full Text] [Related]  

  • 78. Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.
    Avan A; Avan A; Maftouh M; Ghayour Mobarhan M; Shahidsales S; Gholamin S
    J Clin Oncol; 2015 May; 33(15):1711-2. PubMed ID: 25870088
    [No Abstract]   [Full Text] [Related]  

  • 79. Can cancer clinical trials be fixed?
    Allison M
    Nat Biotechnol; 2011 Jan; 29(1):13-5. PubMed ID: 21221090
    [No Abstract]   [Full Text] [Related]  

  • 80. Trastuzumab: qui bono?
    Krop IE; Burstein HJ
    J Natl Cancer Inst; 2013 Dec; 105(23):1772-5. PubMed ID: 24262439
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.